Allergen, Individual-Tree pollen White Pine Pinus strobus T16

The Allergen, Individual-Tree Pollen White Pine (Pinus Strobus) T16 test is a targeted home-accessible assay that detects sensitization to White Pine pollen by measuring specific IgE antibodies in a blood sample. The sample is collected at home by a trained phlebotomist and analysed in an accredited laboratory using validated immunoassay techniques to quantify IgE levels (reported in kU/L and clinical sensitization classes).

This test is important for people with seasonal allergic rhinitis, conjunctivitis or asthma suspected to be triggered by tree pollen, and for clinicians planning personalised management such as environmental control or specific immunotherapy. Available across Dubai and the UAE, the T16 assay helps differentiate White Pine sensitization from other pollens, supports evidence-based avoidance strategies, and informs follow-up with an allergist or respiratory specialist.

• Specific IgE — White Pine (Pinus Strobus) pollen
• IgE concentration (kU/L)
• Sensitization class / Interpretive grade (0–6)
• Allergen code: T16

• Recurrent seasonal sneezing, runny or blocked nose during outdoor exposure
• Itchy, red or watery eyes coinciding with local tree pollen season
• Worsening asthma or wheeze when outdoors near landscaped areas or parks
• Before considering allergen-specific immunotherapy for tree pollen
• When distinguishing tree pollen allergy from other seasonal allergens

• Confirms sensitization specifically to White Pine pollen
• Enables targeted avoidance and environmental control measures
• Supports clinical decisions on immunotherapy and medication management
• Convenient at‑home sample collection and laboratory-standard reporting in the UAE
• Helps reduce unnecessary broad-spectrum treatments by identifying the trigger

• At-home blood sample collection (capillary or venous) by trained phlebotomist
• No fasting required prior to sample collection
• Inform the laboratory/clinician about recent allergen immunotherapy or anti-IgE therapies (e.g., omalizumab)
• Suitable for adults and children; consult your physician for interpretation and next steps